Tuesday, March 7, 2017

Nature Biotechnology Contents: Volume 35 pp 181 - 290

If you are unable to see the message below, click here to view.
Nature Biotechnology


Advertisement
In the middle of innovation, medicine, growth, and so much more, Destination Medical Center (DMC) is transforming Rochester, MN. DMC is a 20-year, $5.6 billion economic development plan. Together, DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education.
TABLE OF CONTENTS

March 2017 Volume 35, Issue 3

In This Issue
Editorial
News
Bioentrepreneur
Opinion and Comment
Features
News and Views
Research
Careers and Recruitment

Advertisement

Having trouble Immunophenotyping across multiple species?

Download our new infographic highlighting the power of profiling immune cell subsets across species. Visit FlowMetric at SOT2017, Booth #2608. 

Download this Infographic now
 


Subscribe
 
Facebook
 
RSS
 
Recommend to library
 
Twitter
 

Advertisement
Bioprocessing Technologies in Stem Cell Research: Challenges and Chances for Commercialization
The 1st Stem Cell Community Day brings together experts from industry and academia to discuss recent achievements, challenges, and chances in stem cell bioprocessing for research and commercial manufacturing. Register now and submit your abstract! 
www.stemcellday.de
 
Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities


 
Advertisement
Nature Outlook: Regenerative Medicine 

Sometimes, a drug can remedy a chemical imbalance or surgery can repair a structural failure, but there are times when there is no substitute for replacing a part with human tissue or an entire organ. Rapid advances in regenerative medicine are bringing that possibility closer to reality. 

Access the Outlook

Produced with support from 
Translational Research Informatics Center(TRI) 
Clio, Inc. 
Sapporo Medical University 
CYBERDYNE,INC.
 

Advertisement
Nature Reviews Microbiology: Collection on Antimicrobial Resistance 

This collection of articles from several Nature journals describes how antimicrobial resistance emerges and details discovery strategies for urgently needed new antimicrobials. 

Access this collection free online for six months

Produced with support from 
Merck & Co., Inc., Kenilworth, NJ, USA
 
Focus on RNA-based therapies
A joint focus with Nature Reviews Drug Discovery on RNA-based therapeutics presents a series of articles detailing recent progress in chemistries and delivery technologies that have propelled the clinical advancement of oligonucleotide therapies as well as highlighting commercial advances in RNA vaccines.

In This Issue

Top

In this issue   ppvii - vii
doi:10.1038/nbt.3831

Editorial

Top

The commercial tipping point   p181
doi:10.1038/nbt.3829
RNA-based therapeutics are poised to become successful commercial products, but wide adoption across the biopharmaceutical industry will likely take a few more years.

News

Top

Billion-dollar deals end eras of Ariad and Actelion   pp183 - 184
Melanie Senior
doi:10.1038/nbt0317-183

CRISPR patents belong to Broad, says USPTO   p184
doi:10.1038/nbt0317-184

Gender tokenism and bias prevail in biotech boardrooms   pp185 - 186
Elie Dolgin
doi:10.1038/nbt0317-185

Merck KGaA lands four Vertex cancer programs   p186
doi:10.1038/nbt0317-186

Solithromycin rejection chills antibiotic sector   pp187 - 188
Brian Owens
doi:10.1038/nbt0317-187

Trump's pick rallies biosimilar makers   p189
doi:10.1038/nbt0317-189b

Biogen pays Forward in Tecfidera dispute   p189
doi:10.1038/nbt0317-189c

Celgene eyes 'inverse vaccines' in Anokion and Delinia deals   pp189 - 190
Cormac Sheridan
doi:10.1038/nbt0317-189a

New York spreads the news with $1.15 billion biotech plan   p191
Gautam Naik
doi:10.1038/nbt0317-191

Podcast

First Rounders podcast: Stephen Quake   p192
doi:10.1038/nbt.3808

Around the world in a month   p192
doi:10.1038/nbt0317-192

News Features

The 'anti-hype' vaccine   pp193 - 197
Laura DeFrancesco
doi:10.1038/nbt.3812
After years under the radar, RNA vaccines are finally emerging as immunotherapies to combat pandemics and cancer. But as Laura DeFrancesco reports, clinical validation remains elusive.

Worth the RISC?   pp198 - 202
Ken Garber
doi:10.1038/nbt.3810
The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.


Advertisement
Faster, Simpler Biological LC-MS/MS Analysis
Shimadzu's Clinical Laboratory Automation Module, a fully integrated sample pretreatment module for LC-MS/MS, automatically performs all of the processes necessary for analyzing blood and other biological samples, providing more precise results by reducing human error and improving laboratory safety and efficiency. Learn more.
 

Bioentrepreneur

Top
Data page

Top US universities, institutes for life sciences in 2015   p203
Brady Huggett
doi:10.1038/nbt.3818

Opinion and Comment

Top
Correspondence

US immigration order strikes against biotech   pp204 - 206
Jeremy M Levin, Steven H Holtzman, John Maraganore, Paul J Hastings, Ron Cohen et al.
doi:10.1038/nbt.3824

Why axing TPP was a lost opportunity for biotech   pp206 - 207
Kevin E Noonan
doi:10.1038/nbt.3821

Response to “Railroading at the FDA”   pp207 - 209
Francesco Muntoni, Sue Fletcher and Steve Wilton
doi:10.1038/nbt.3819

Features

Top
Patents

Evidence of insufficient quality of reporting in patent landscapes in the life sciences OPEN   pp210 - 214
James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr and David A Brindley
doi:10.1038/nbt.3809
Despite the importance of patent landscape analyses in the commercialization process for life science and healthcare technologies, the quality of reporting for patent landscapes published in academic journals is inadequate.

Recent patents in chimeric antigen receptors   p215
doi:10.1038/nbt.3832


Advertisement
nature.com webcasts

Springer Nature presents a custom webcast on: Advances in neuroscience research utilizing modern in situ RNA gene expression techniques.

Date: 23rd March 2017
Time: 10AM PDT | 1PM EDT | 5PM GMT | 6PM CET

Register for FREE and discover how Dr. Jerold Chun has used RNAscope to investigate the human brain

Sponsor: 
Advanced Cell Diagnostics
 
 

News and Views

Top

Hearing in the mouse of Usher   pp216 - 218
John V Brigande
doi:10.1038/nbt.3815
Hearing and balance are rescued by a synthetic virus that delivers a transgene to the inner ear of neonatal mice.

See also: Research by Pan et al. | Research by Landegger et al.

Fleeting factors, turning back time   pp218 - 220
Thomas A Rando
doi:10.1038/nbt.3817
Old cells and tissues become young again after a short dose of reprogramming factors.

The alleles of a tasty tomato   pp220 - 221
Katarzyna Marcinkiewicz
doi:10.1038/nbt.3814

Research Highlights   p221
doi:10.1038/nbt.3813

Research

Top
Perspectives

Overcoming cellular barriers for RNA therapeutics   pp222 - 229
Steven F Dowdy
doi:10.1038/nbt.3802
Recent progress in delivering RNA therapeutics to the inside of cells might lead to more success in clinical applications.

Cellular uptake and trafficking of antisense oligonucleotides   pp230 - 237
Stanley T Crooke, Shiyu Wang, Timothy A Vickers, Wen Shen and Xue-hai Liang
doi:10.1038/nbt.3779

Reviews

The chemical evolution of oligonucleotide therapies of clinical utility   pp238 - 248
Anastasia Khvorova and Jonathan K Watts
doi:10.1038/nbt.3765
Refinements in the chemistries employed in oligonucleotide therapeutics have galvanized clinical progress. The complex interplay between chemical modifications and integration into sequence architecture is discussed in the context of antisense and small-interfering RNA drugs.

Oligonucleotide therapies for disorders of the nervous system   pp249 - 263
Olga Khorkova and Claes Wahlestedt
doi:10.1038/nbt.3784
Brain-targeted oligonucleotide-drugs are poised to treat multiple human central nervous system disorders with an emphasis on rare/orphan conditions.

Articles

Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c   pp264 - 272
Bifeng Pan, Charles Askew, Alice Galvin, Selena Heman-Ackah, Yukako Asai et al.
doi:10.1038/nbt.3801
Gene therapy in the inner ear achieves unprecedented recovery of hearing and balance behavior in Usher syndrome mice.

See also: News and Views by Brigande

Dynamic regulation of metabolic flux in engineered bacteria using a pathway-independent quorum-sensing circuit   pp273 - 279
Apoorv Gupta, Irene M Brockman Reizman, Christopher R Reisch and Kristala L J Prather
doi:10.1038/nbt.3796
An inducer-free quorum-sensing circuit is applied to control endogenous bacterial gene expression and improve yields of a range of products.

Letter

A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear   pp280 - 284
Lukas D Landegger, Bifeng Pan, Charles Askew, Sarah J Wassmer, Sarah D Gluck et al.
doi:10.1038/nbt.3781
Efficient gene transfer to the mouse inner ear is achieved with a synthetic adeno-associated viral vector.

See also: News and Views by Brigande

Careers and Recruitment

Top

International mentoring as a new educational approach to alleviate brain drain, empower young talent, and internationalize higher education   pp285 - 288
Maria Soriano-Carot, Rosa Breton-Romero, Joaquin Lopez-Herraiz, Rocio Lopez-Diego, Abel Suarez-Fueyo et al.
doi:10.1038/nbt.3822
A novel program shows that young professionals working abroad can be instrumental in their home country's development.

People

People   p290
doi:10.1038/nbt.3830

Advertisement
nature.com webcasts

Circulating Tumour Cells: Liquid biopsy by high-throughput, high-resolution imaging flow cytometry

Date: Tuesday, March 28, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

Register for FREE


Sponsored by:

Merck KGaA, Darmstadt, Germany.
he life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada 
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: